Memorial Sloan Kettering Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private

Established: 1884-01-01

Employees: 10K

Market Cap: -

Website: http://www.mskcc.org

Clinical Trials

Pilot Study of Optune (NovoTTF-100A) for Recurrent Atypical and Anaplastic Meningioma

Not Applicable

Active, not recruiting

Conditions: Brain Cancer

Interventions: Device: Optune (NovoTTF-100A)

First Posted Date: 2013-07-04

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 6

Registration Number: NCT01892397

Locations: 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Commack, Commack, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 5 locations

Ablation of Renal Masses Outcomes Registry (ARMOR): Ablation Procedure and Quality of Life Assessment

Active, not recruiting

Conditions: Renal Cancer

Interventions: Behavioral: (EORTC QLQ-C30) questionnaire
Behavioral: EuroQol EQ-5D 7-item questionnaire

First Posted Date: 2013-06-27

Last Posted Date: 2024-07-25

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 294

Registration Number: NCT01888198

Locations: 🇺🇸
Md Anderson Cancer Center, Houston, Texas, United States
🇺🇸
University of California, Los Angeles, Los Angeles, California, United States
🇺🇸
University of Maryland Medical Center, Baltimore, Maryland, United States

and more 3 locations

Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Non-Anaplastic Non-Medullary Thyroid Cancer

Phase 2

Completed

Conditions: Thyroid Cancer

Interventions: Radiation: IMRT
Device: DWI MRI
Drug: Doxorubicin
Other: Modified Barium Swallow Impairment Profile (MBSImP)

First Posted Date: 2013-06-20

Last Posted Date: 2022-12-29

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 27

Registration Number: NCT01882816

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Commack, Commack, New York, United States

and more 3 locations

Decision Making in Men With Early Stage Prostate Cancer Patients and Partners/Close Allies

Active, not recruiting

Conditions: Low Risk Prostate Cancer

Interventions: Behavioral: assessments

First Posted Date: 2013-06-13

Last Posted Date: 2024-05-24

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 541

Registration Number: NCT01877070

Locations: 🇺🇸
Memorial Sloan Kettering Westchester, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Mount Sinai Hospital, New York, New York, United States

Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

Phase 2

Active, not recruiting

Conditions: Germ Cell Tumors

Interventions: Drug: Paclitaxel
Drug: Ifosfamide
Drug: Bleomycin
Drug: Etoposide
Drug: Cisplatin
Drug: Mesna

First Posted Date: 2013-06-10

Last Posted Date: 2024-07-03

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 92

Registration Number: NCT01873326

Locations: 🇺🇸
University of Southern California, Los Angeles, California, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States
🇺🇸
Memorial Sloan Kettering Cancer Center @ Suffolk, Commack, New York, United States

and more 9 locations

Reflectance Confocal Microscopy of Wounds During Moh's Surgery: Feasibility Testing of a Mosaicing Algorithm for Intraoperative Imaging of Cancer Margins

Completed

Conditions: Basal Cell Carcinoma
Squamous Cell Carcinoma

First Posted Date: 2013-06-07

Last Posted Date: 2020-05-01

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 45

Registration Number: NCT01872130

Locations: 🇺🇸
Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering West Harrison, Harrison, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center Hauppauge, Hauppauge, New York, United States

and more 1 locations

BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer

Phase 1

Completed

Conditions: Metastatic or Locally-advanced Unresectable Breast Cancer

Interventions: Drug: BYL719
Drug: Letrozole
Drug: Exemestane

First Posted Date: 2013-06-06

Last Posted Date: 2024-12-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 52

Registration Number: NCT01870505

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Brentuximab Vedotin Combined With AVD Chemotherapy in Patients With Newly Diagnosed Early Stage, Unfavorable Risk Hodgkin Lymphoma

Not Applicable

Active, not recruiting

Conditions: Hodgkin Lymphoma

Interventions: Drug: Brentuximab vedotin (SGN-35)
Drug: Doxorubicin HCL
Drug: Vinblastine Sulfate
Drug: Dacarbazine
Radiation: Involved-Site Radiation Therapy (ISRT)
Procedure: Interim PET
Radiation: consolidation volume RT (CVRT)

First Posted Date: 2013-06-04

Last Posted Date: 2024-07-09

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 118

Registration Number: NCT01868451

Locations: 🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Stanford University Medical Center, Stanford, California, United States

and more 7 locations

Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma

Phase 1

Completed

Conditions: Relapsed or Refractory Multiple Myeloma

Interventions: Drug: Cabozantinib (XL184)

First Posted Date: 2013-05-31

Last Posted Date: 2017-08-30

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 11

Registration Number: NCT01866293

Locations: 🇺🇸
Memoral Sloan Kettering Cancer Center, Basking Ridge, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
Memorial Sloan Kettering Cancer Center at Mercy Medical Center, Rockville Centre, New York, United States

and more 2 locations

FACBC PET and PEM as a Staging Tool and Indicator of Therapeutic Response in Breast Cancer Patients

Early Phase 1

Completed

Conditions: Breast Cancer

Interventions: Procedure: Positron Emission Tomography (PET)
Drug: Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)
Procedure: Positron emission mammography (PEM) When available
Procedure: MR

First Posted Date: 2013-05-29

Last Posted Date: 2017-08-31

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 30

Registration Number: NCT01864083

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy